Sep 08,2022

U-Haul Team Members Enrolled with Virta Health Eliminate Over One-Third of Diabetes Medications in Just 90 Days

Type 2 diabetes reversal leader Virta Health and U-Haul International, Inc. announced 90-day outcomes from their partnership, including blood sugar reduction, weight loss, and medication deprescription for participating U-Haul Team Members. Amid skyrocketing employee medical expenses, employers are struggling to control costs. Diabetes medications are seeing some of the steepest increases, with insulin prices rising more than 50% between 2014-2019. Meanwhile, under the standard of care, patients are typically prescribed more medications each year to manage their diabetes as it progresses, leading to a vicious cycle of rising costs and worse health outcomes.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 19,2022

New Study Suggests REN Comparable to Standard Care Prescribed Medications for Acute Treatment of Chronic Migraines

Theranica, a prescribed digital therapeutics company developing advanced digitally-connected neuromodulation devices for migraine and other pain conditions, announced today the publication of a new study comparing the effectiveness of Remote Electrical Neuromodulation (REN) to that of standard-care medications for the acute treatment of chronic migraine. The post-hoc analysis published in the Journal of Pain Management concludes that REN, administered by Theranica's flagship therapeutic wearable Nerivio®, provides an effective non-pharmacological alternative for standard-care abortive medications in individuals impacted by chronic migraine.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Sep 21,2022

New Study Published in an American Heart Association Journal Indicates that Hello Heart’s Digital Coaching App Could Contribute to Heart Health Equity

Hello Heart, the only digital therapeutic that focuses exclusively on heart health, has released a new study evaluating the program's results for various user population groups in order to demonstrate its effectiveness related to diversity, equity, and inclusion (DEI). The study, published as an abstract in the American Heart Association’s Hypertension journal, indicates that Hello Heart’s hypertension digital coaching program could contribute to health equity, showing similar improvements in heart health for a range of populations, across gender, age, race, and more.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 22,2022

DarioHealth Publishes New Clinical Research Linking the Use of its Biofeedback Device to Reduced Back Pain

DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research examining the link between the use of Dario's biofeedback device to help users improve their posture and reduced back pain at the International Association of the Study of Pain (IASP) 2022 World Congress on Pain, being held in person in Toronto, Ontario from September 19th – 23rd and virtually.

CLINICAL STUDY

#connected device

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 04,2022

Positive Results from Pivotal Trial of Better Therapeutics’ Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes Care

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced that the positive 90 day results from its pivotal trial for BT-001, a potentially first-of-its-kind digital therapeutic platform that is designed to use CBT to treat type 2 diabetes (T2D) in patients 18 years and older, have been published in the American Diabetes Association (ADA)-produced, peer reviewed journal Diabetes Care. This trial was the largest randomized, controlled study conducted to date looking at use of digitally delivered CBT to improve glycemic control in T2D. Patients using BT-001 saw A1c lowered on average by 0.4% compared to the control group after 90 days, with a greater reduction among patients who completed more modules of the therapy.

CLINICAL STUDY

#pdt

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 18,2022

Theranica Achieves Positive Results in Placebo-Controlled Pivotal Trial of Nerivio® for Preventive Treatment of Migraine

Theranica Bio-electronics, a prescribed digital therapeutics company developing advanced digitally connected neuromodulation devices for migraine and other pain conditions, today announced positive top-line results in its double-blind, randomized, placebo-controlled, multi-center, pivotal clinical trial in the USA (NCT04828707). This trial evaluated the efficacy and safety of Nerivio® for the preventive treatment of migraine in both episodic and chronic migraine patients. The study met the primary endpoint, demonstrating a statistically significant reduction from baseline in monthly migraine days in patients treated with Nerivio®, compared with a placebo device.

CLINICAL STUDY

#pdt

#connected device

View Analyst & Ambassador Comments
Go to original news
Oct 24,2022

Pear Therapeutics Announces Publication Of Real-World Data Showing High Rates Of Engagement, Retention And Abstinence With Reset®

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication of results from a real-world observational analysis of engagement, retention and substance use among patients with substance use disorder (SUD) treated with reSET®, the first and only FDA-authorized PDT for the treatment of SUD (including alcohol, cannabis, cocaine, and stimulants like methamphetamines). The real-world data, which demonstrated high rates of engagement, retention and abstinence from substances with reSET treatment through 12 weeks, was published in The American Journal on Addictions (AJA).

CLINICAL STUDY

#pdt

#rwe

View Analyst & Ambassador Comments
Go to original news
Nov 29,2022

First study to utilize digital therapeutics on rare lung disease begins national patient enrollment

A first-of-its-kind digital therapeutics research study may offer new hope for patients with a rare lung disease and are having difficulty with anxiety. Vicore Pharma recently launched the study across the U.S. The Vicore COMPANION Study will test Almee™, a digital cognitive behavioral therapy (CBT). The COMPANION study, a fully digitized, randomized, controlled parallel-group clinical investigation, will examine the impact of Almee™ on anxiety in patients with PF by looking at the change from baseline in anxiety symptom severity assessed by GAD-7. 

CLINICAL STUDY

#cbt

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 01,2021

Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination with sublingual buprenorphine/naloxone, as part of a clinician-supervised medication-assisted treatment program for the treatment of opioid use disorder (OUD).

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 14,2021

Pear Therapeutics Reports Nine-Month Real-World Healthcare Utilization Data for reSET-O®

Pear Therapeutics, Inc. today announced results from an extended retrospective analysis of real-world data analyzing healthcare resource utilization for reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). Results from a nine-month real-world data analysis show a continued long-term reduction in costly healthcare utilization categories including inpatient (IP) stays and emergency department (ED) visits in patients with OUD. The analysis, published in the peer-reviewed journal Expert Review of Pharmacoeconomics & Outcomes Research, suggests a possible durability of the reSET-O treatment effect and a long-term stabilization of the clinical trajectory for patients in recovery from OUD, and indicate a strong potential for the cost effectiveness of reSET-O in real-world care settings.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY